FIGURE 4
FROM:
Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation
K J Thomson, K S Peggs, P Smith, J Cavet, A Hunter, A Parker, R Pettengell, D Milligan, E C Morris, A H Goldstone, D C Linch and S Mackinnon
BACK TO ARTICLEFigure 4.
Non-relapse mortality (NRM) following reduced-intensity transplantation (RIT, n=38). NRM is 13% at 1 year, 19% at 5 years.
